Astrana Health Financials

ASTH

Export CSV

Key Financial Metrics

Revenue

$2.0B

YoY+46.7%

5Y CAGR+29.4%

10Y CAGR+51.0%

Astrana Health generated $2.0B in revenue in fiscal year 2024. This represents an increase of 46.7% from the prior year.

EBITDA

$117.3M

YoY+14.6%

5Y CAGR+18.3%

Astrana Health's EBITDA was $117.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.6% from the prior year.

Free Cash Flow

$44.2M

YoY+11.3%

5Y CAGR+28.4%

Astrana Health generated $44.2M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents an increase of 11.3% from the prior year.

Net Income

$43.1M

YoY-28.9%

5Y CAGR+25.0%

Astrana Health reported $43.1M in net income in fiscal year 2024. This represents a decrease of 28.9% from the prior year.

EPS (Diluted)

$0.90

YoY-30.2%

5Y CAGR+18.2%

Astrana Health earned $0.90 per diluted share in fiscal year 2024. This represents a decrease of 30.2% from the prior year.

Cash & Debt

$288.5M

YoY-1.8%

5Y CAGR+22.8%

10Y CAGR+50.0%

Astrana Health held $288.5M in cash against $425.3M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

N/A

Gross Margin

13.3%

YoY-2.2pp

5Y CAGR-3.2pp

Astrana Health's gross margin was 13.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 2.2 percentage points from the prior year.

Operating Margin

4.4%

YoY-1.7pp

5Y CAGR-1.4pp

10Y CAGR+6.5pp

Astrana Health's operating margin was 4.4% in fiscal year 2024, reflecting core business profitability. This is down 1.7 percentage points from the prior year.

Net Margin

2.1%

YoY-2.3pp

5Y CAGR-0.4pp

10Y CAGR+7.6pp

Astrana Health's net profit margin was 2.1% in fiscal year 2024, showing the share of revenue converted to profit. This is down 2.3 percentage points from the prior year.

Return on Equity

6.0%

YoY-3.8pp

5Y CAGR-1.3pp

Astrana Health's return on equity was 6.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 3.8 percentage points from the prior year.

R&D Spending

N/A

Share Buybacks

$900K

YoY-91.2%

5Y CAGR-34.7%

10Y CAGR+111.6%

Astrana Health spent $900K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 91.2% from the prior year.

Capital Expenditures

$8.0M

YoY-71.8%

5Y CAGR+50.4%

10Y CAGR+68.1%

Astrana Health invested $8.0M in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 71.8% from the prior year.

ASTH Income Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Revenue	$2.0B+46.7%	$1.4B+21.2%	$1.1B+47.8%	$773.9M+12.6%	$687.2M+22.6%	$560.6M
Cost of Revenue	$1.8B+50.5%	$1.2B+24.0%	$944.7M+58.5%	$596.1M+10.6%	$539.2M+15.3%	$467.8M
Gross Profit	$271.4M+26.3%	$215.0M+7.8%	$199.5M+12.2%	$177.8M+20.1%	$148.0M+59.4%	$92.8M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$154.1M+36.9%	$112.6M+45.0%	$77.7M+25.1%	$62.1M+26.4%	$49.1M+18.4%	$41.5M
Operating Income	$89.3M+5.6%	$84.6M-18.8%	$104.3M+6.2%	$98.2M+22.0%	$80.5M+148.3%	$32.4M
Interest Expense	$33.1M+105.5%	$16.1M+103.3%	$7.9M+46.8%	$5.4M-43.2%	$9.5M+100.7%	$4.7M
Income Tax	$30.9M-3.4%	$32.0M-21.7%	$40.9M+29.0%	$31.7M-43.8%	$56.3M+589.9%	$8.2M
Net Income	$43.1M-28.9%	$60.7M+34.4%	$45.2M-34.5%	$68.9M+82.9%	$37.7M+167.0%	$14.1M
EPS (Diluted)	$0.90-30.2%	$1.29+30.3%	$0.99-34.9%	$1.52+50.5%	$1.01+159.0%	$0.39

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$956.0M+46.0%	$654.8M+5.5%	$620.4M	N/A	$478.7M-1.6%	$486.3M+20.3%	$404.4M	N/A
Cost of Revenue	$858.9M+48.9%	$576.8M+5.1%	$549.1M	N/A	$405.2M-1.8%	$412.8M+24.9%	$330.4M	N/A
Gross Profit	$97.2M+24.7%	$78.0M+9.3%	$71.3M	N/A	$73.5M0.0%	$73.5M-0.7%	$74.0M	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$62.4M+23.0%	$50.7M+15.6%	$43.9M	N/A	$37.8M+5.1%	$36.0M-7.2%	$38.7M	N/A
Operating Income	$19.2M-5.6%	$20.3M-1.2%	$20.6M	N/A	$28.4M-5.5%	$30.1M-0.2%	$30.1M	N/A
Interest Expense	$17.7M+140.0%	$7.4M+1.0%	$7.3M	N/A	$8.9M+3.1%	$8.6M+13.2%	$7.6M	N/A
Income Tax	$4.6M-30.5%	$6.6M+95.4%	$3.4M	N/A	$7.8M-21.9%	$10.0M+40.5%	$7.1M	N/A
Net Income	$373K-96.0%	$9.4M+40.8%	$6.7M	N/A	$16.1M-16.1%	$19.2M+29.2%	$14.8M	N/A
EPS (Diluted)	$0.01-94.7%	$0.19+35.7%	$0.14	N/A	$0.33-17.5%	$0.40+29.0%	$0.31	N/A

ASTH Balance Sheet

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Total Assets	$1.4B+45.2%	$933.4M-3.4%	$966.2M+11.4%	$867.4M+6.1%	$817.5M+12.2%	$728.7M
Current Assets	$638.5M+38.4%	$461.5M+7.8%	$428.1M+5.9%	$404.5M+19.5%	$338.6M+2.9%	$329.1M
Cash & Equivalents	$288.5M-1.8%	$293.8M+2.0%	$288.0M+23.6%	$233.1M+20.5%	$193.5M+87.5%	$103.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$276.0M	N/A	$49.6M+367.9%	$10.6M+50.3%	$7.1M-35.9%	$11.0M
Goodwill	$419.3M+50.4%	$278.8M+3.6%	$269.1M+9.2%	$246.4M+6.0%	$232.4M-2.5%	$238.5M
Total Liabilities	$840.7M+60.9%	$522.6M+28.2%	$407.7M+14.3%	$356.7M-4.2%	$372.3M-30.6%	$536.4M
Current Liabilities	$365.6M+67.2%	$218.7M+47.1%	$148.6M+29.5%	$114.7M-0.2%	$115.0M+9.1%	$105.4M
Long-Term Debt	$425.3M+64.2%	$258.9M+27.3%	$203.4M+11.2%	$182.9M-20.5%	$230.2M-0.8%	$232.2M
Total Equity	$712.7M+15.6%	$616.7M+13.3%	$544.3M+19.9%	$454.1M+37.8%	$329.5M+71.3%	$192.3M
Retained Earnings	$286.3M+17.7%	$243.1M+33.3%	$182.4M+32.9%	$137.2M+96.7%	$69.8M+118.7%	$31.9M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$2.2B+55.1%	$1.4B+8.3%	$1.3B-1.7%	$1.4B+5.4%	$1.3B+2.6%	$1.3B+2.1%	$1.2B+31.4%	$933.4M
Current Assets	$883.6M+21.2%	$729.2M+18.9%	$613.3M-4.0%	$638.5M+7.0%	$597.0M+4.7%	$570.3M+5.9%	$538.8M+16.8%	$461.5M
Cash & Equivalents	$462.2M+36.1%	$339.7M+31.4%	$258.5M-10.4%	$288.5M-17.1%	$348.0M+7.0%	$325.3M-2.8%	$334.8M+14.0%	$293.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$381.2M+9.3%	$348.7M	N/A	$276.0M	N/A	N/A	N/A	N/A
Goodwill	$863.3M+107.1%	$416.9M+0.1%	$416.4M-0.7%	$419.3M+2.3%	$409.7M0.0%	$409.6M-0.2%	$410.3M+47.1%	$278.8M
Total Liabilities	$1.7B+86.0%	$904.4M+11.2%	$813.5M-3.2%	$840.7M+8.0%	$778.3M+0.6%	$773.8M0.0%	$773.9M+48.1%	$522.6M
Current Liabilities	$629.9M+37.0%	$459.7M+27.3%	$361.3M-1.2%	$365.6M+16.8%	$312.9M+1.0%	$309.8M-12.8%	$355.3M+62.5%	$218.7M
Long-Term Debt	$1.0B+149.8%	$401.1M-0.7%	$403.9M-5.0%	$425.3M+0.5%	$423.1M-0.4%	$425.0M+15.4%	$368.4M+42.3%	$258.9M
Total Equity	$775.5M+0.5%	$771.5M+2.8%	$750.4M+5.3%	$712.7M+0.4%	$709.6M+3.9%	$683.0M+3.8%	$658.0M+6.7%	$616.7M
Retained Earnings	$302.5M+0.1%	$302.2M+3.2%	$292.9M+2.3%	$286.3M-2.4%	$293.2M+5.8%	$277.1M+7.4%	$258.0M+6.1%	$243.1M

ASTH Cash Flow Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Operating Cash Flow	$52.2M-23.5%	$68.2M-16.9%	$82.1M+16.8%	$70.3M+52.4%	$46.2M+237.6%	$13.7M
Capital Expenditures	$8.0M-71.8%	$28.5M+24.4%	$22.9M+19.3%	$19.2M+1551.5%	$1.2M+11.7%	$1.0M
Free Cash Flow	$44.2M+11.3%	$39.7M-32.9%	$59.2M+15.8%	$51.1M+13.6%	$45.0M+256.3%	$12.6M
Investing Cash Flow	-$192.4M-193.6%	-$65.5M-821.2%	-$7.1M-143.0%	$16.5M-82.7%	$95.5M+152.9%	-$180.6M
Financing Cash Flow	$135.1M+3850.5%	$3.4M+117.0%	-$20.1M+57.9%	-$47.7M+7.6%	-$51.7M-131.7%	$163.3M
Dividends Paid	$4.0M-93.5%	$62.1M+342.4%	$14.0M-54.9%	$31.1M-39.4%	$51.3M-16.8%	$61.7M
Share Buybacks	$900K-91.2%	$10.2M+10.2%	$9.3M+61.2%	$5.7M+968.7%	$537K-92.9%	$7.6M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	$16.6M	N/A	N/A	N/A	$6.0M	N/A
Capital Expenditures	N/A	N/A	$3.1M	N/A	N/A	N/A	$369K	N/A
Free Cash Flow	N/A	N/A	$13.6M	N/A	N/A	N/A	$5.6M	N/A
Investing Cash Flow	N/A	N/A	-$2.4M	N/A	N/A	N/A	-$71.0M	N/A
Financing Cash Flow	N/A	N/A	-$44.2M	N/A	N/A	N/A	$106.4M	N/A
Dividends Paid	N/A	N/A	$5.5M	N/A	N/A	N/A	$95K	N/A
Share Buybacks	N/A	N/A	$10.6M	N/A	N/A	N/A	N/A	N/A

ASTH Financial Ratios

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Gross Margin	13.3%-2.2pp	15.5%-1.9pp	17.4%-5.5pp	23.0%+1.4pp	21.5%+5.0pp	16.6%
Operating Margin	4.4%-1.7pp	6.1%-3.0pp	9.1%-3.6pp	12.7%+1.0pp	11.7%+5.9pp	5.8%
Net Margin	2.1%-2.3pp	4.4%+0.4pp	4.0%-5.0pp	8.9%+3.4pp	5.5%+3.0pp	2.5%
Return on Equity	6.0%-3.8pp	9.8%+1.6pp	8.3%-6.9pp	15.2%+3.7pp	11.4%+4.1pp	7.3%
Return on Assets	3.2%-3.3pp	6.5%+1.8pp	4.7%-3.3pp	8.0%+3.3pp	4.6%+2.7pp	1.9%
Current Ratio	1.75-0.4	2.11-0.8	2.88-0.6	3.53+0.6	2.94-0.2	3.12
Debt-to-Equity	0.60+0.2	0.42+0.0	0.37-0.0	0.40-0.3	0.70-0.5	1.21
FCF Margin	2.2%-0.7pp	2.9%-2.3pp	5.2%-1.4pp	6.6%+0.1pp	6.6%+4.3pp	2.3%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	10.2%-1.7pp	11.9%+0.4pp	11.5%	N/A	15.3%+0.2pp	15.1%-3.2pp	18.3%	N/A
Operating Margin	2.0%-1.1pp	3.1%-0.2pp	3.3%	N/A	5.9%-0.2pp	6.2%-1.3pp	7.4%	N/A
Net Margin	0.0%-1.4pp	1.4%+0.4pp	1.1%	N/A	3.4%-0.6pp	3.9%+0.3pp	3.7%	N/A
Return on Equity	0.1%-1.2pp	1.2%+0.3pp	0.9%	N/A	2.3%-0.5pp	2.8%+0.6pp	2.3%	N/A
Return on Assets	0.0%-0.6pp	0.7%+0.1pp	0.5%	N/A	1.3%-0.3pp	1.5%+0.3pp	1.2%	N/A
Current Ratio	1.40-0.2	1.59-0.1	1.70-0.0	1.75-0.2	1.91+0.1	1.84+0.3	1.52-0.6	2.11
Debt-to-Equity	1.29+0.8	0.52-0.0	0.54-0.1	0.600.0	0.60-0.0	0.62+0.1	0.56+0.1	0.42
FCF Margin	N/A	N/A	2.2%	N/A	N/A	N/A	1.4%	N/A

Frequently Asked Questions

What is Astrana Health's annual revenue?

Astrana Health (ASTH) reported $2.0B in revenue for fiscal year 2024.

How fast is Astrana Health's revenue growing?

Astrana Health (ASTH) revenue grew by 46.7% year-over-year, from $1.4B to $2.0B in fiscal year 2024.

Is Astrana Health profitable?

Yes, Astrana Health (ASTH) reported a net income of $43.1M in fiscal year 2024, with a net profit margin of 2.1%.

What is Astrana Health's earnings per share (EPS)?

Astrana Health (ASTH) reported diluted earnings per share of $0.90 for fiscal year 2024.

What is Astrana Health's EBITDA?

Astrana Health (ASTH) had EBITDA of $117.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Astrana Health have?

As of fiscal year 2024, Astrana Health (ASTH) had $288.5M in cash and equivalents against $425.3M in long-term debt.

What is Astrana Health's gross margin?

Astrana Health (ASTH) had a gross margin of 13.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Astrana Health's operating margin?

Astrana Health (ASTH) had an operating margin of 4.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Astrana Health's net profit margin?

Astrana Health (ASTH) had a net profit margin of 2.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Astrana Health's return on equity (ROE)?

Astrana Health (ASTH) has a return on equity of 6.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Astrana Health's free cash flow?

Astrana Health (ASTH) generated $44.2M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Astrana Health's operating cash flow?

Astrana Health (ASTH) generated $52.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Astrana Health's total assets?

Astrana Health (ASTH) had $1.4B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Astrana Health's capital expenditures?

Astrana Health (ASTH) invested $8.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Does Astrana Health buy back shares?

Yes, Astrana Health (ASTH) spent $900K on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

What is Astrana Health's current ratio?

Astrana Health (ASTH) had a current ratio of 1.75 as of fiscal year 2024, which is generally considered healthy.

What is Astrana Health's debt-to-equity ratio?

Astrana Health (ASTH) had a debt-to-equity ratio of 0.60 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Astrana Health's return on assets (ROA)?

Astrana Health (ASTH) had a return on assets of 3.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.